Dec 19, 2022 | Linda Huguelet
In some ways, a decade seems like a lifetime, but in other ways time flies by. 2013 was my first American Society of Hematology (ASH) Annual Meeting. That annual meeting, like the one this year, was held in New Orleans. The location may have been the same, but the...
Dec 19, 2022 | Michael Tuohy
Targets in myeloma are interesting and hopeful for our futures as bispecific antibodies continue to become a key treatment option. Using the immune system to fight multiple myeloma makes great sense to me. It’s exciting to follow trials targeting BCMA as part of the...
Dec 16, 2022 | Jack Aiello
PREFACE This is my 17th year attending American Society of Hematology (ASH) Annual Meeting, where typically over 30,000 attendees from all over the world (hematologists/oncologists, lab researchers, oncology nurses, scientists, and 300 pharma companies) attend. This...
Dec 13, 2022 | John DeFlice
“The cause is hidden; the effect is visible to all.” Mike Horn Multiple myeloma is a cytogenetically complex blood cancer of the plasma cell, and thesecytogenetic aberrations make it more difficult to treat. Cytogenetics is the study of thebone marrow looking for...
Dec 12, 2022 | John DeFlice
“The impossible exists only until we find a way to make it possible.” Mike Horn Emily Whitehead was five years old when she was diagnosed with acute lymphoblastic leukemia (ALL). After being treated with chemotherapy for two years, she experienced a failure of therapy...
